Idorsia Ltd. · SIX:IDIA

Idorsia — Technical Presentation (June 2018)

29 slides from Idorsia's technical presentation, June 2018

  1. Slide 1: Phase 3 investigation of nemorexant for patients with insomnia

    Phase 3 investigation of nemorexant for patients with insomnia Investor Webcast – June 2018

  2. Slide 2: Forward-looking statements

    The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,

  3. Slide 3: More knowledge – Powered by science

    More knowledge – Powered by science Jean-Paul Clozel CEO 3 Phase 3 initiation in insomnia | June 2018

  4. Slide 4: Our Strategic Priorities

    Our Strategic Priorities 1 Deliver at least three products to market 5 key priorities to ensure the company’s success 2 Build a commercial organization over the next 5 years 3 Bring Idorsia to profitability in a sustainable manner 4 Create a pipeline with a sales potential of CHF 5 billion 5 Utilize

  5. Slide 5: Phase 3 investigation of nemorexant for patients with insomnia

    Phase 3 investigation of nemorexant for patients with insomnia Guy Braunstein Head of Global Clinical Development 5 Phase 3 initiation in insomnia | June 2018

  6. Slide 6: Chronic insomnia disorder

    Chronic insomnia disorder More than 1 type of disturbance present ≥ 3 nights/week for ≥ 3 months Difficulty Difficulty Waking Falling Asleep Staying Asleep Too Early Sleep-Onset Sleep-Maintenance Sleep-Offset Insomnia Insomnia Insomnia Distress or Impairment of life 6 Phase 3 initiation in insomnia

  7. Slide 7: Who gets insomnia and what is the impact?

    Who gets insomnia and what is the impact ? Insomnia is a common problem Risk factors Impact • Age (more common with ageing) • Physically and mentally fatigued, • Gender (women > men) anxious and irritable • Lower socio-economic status • Increased the risk of malaise, fall, accidents, and injury • Ph

  8. Slide 8: How is insomnia treated, what are the limitations?

    How is insomnia treated, what are the limitations? Sleep hygiene Cognitive Pharmacological therapy • Active behavioral therapy • Many have significant limitations patient • Recommended first- • Insufficient acute effect: participation line therapy but lack of sustained effect through the night requi

  9. Slide 9: The orexin system is crucial for the regulation of wakefulness

    The orexin system is crucial for the regulation of wakefulness Orexin stimulates orexin many wake-promoting pathways Dopamine (VTA) Histamine Acetylcholine (LDT, PPT) (TMN) LHA / PH Orexin Serotonin (raphe) LC OX1R Norepinephrine (LC) TMN OX2R Raphe OX1R and OX2R LTD / PPT OX1R and OX2R VTA OX1R and

  10. Slide 10: Nemorexant: dual orexin receptor antagonist

    Nemorexant Dual orexin receptor antagonist Brain The orexin system is involved in the penetrating regulation of sleep and arousal Potent antagonist at OX1 and OX2 Dual orexin receptor antagonism specifically targets receptors excessive alertness, in contrast to treatments of insomnia that act via br

  11. Slide 11: Nemorexant desired profile

    Nemorexant Translation: preclinical healthy subjects patients Desired profile High in vitro potency in vivo efficacy Quick absorption and short half-life fast onset of action, “appropriate” duration of action to act throughout the night, and to avoid next morning residual effect Safety is key • No d

  12. Slide 12: Nemorexant clinical development program

    Nemorexant Clinical development Clinical pharmacology Today program Entry into man Phase 2 studies studies Phase 3 • Single and multiple • Two studies, in adults confirmatory ascending dose and elderly patients studies • Adults and elderly subjects with insomnia • Night time administration • All inf

  13. Slide 13: Ideal pharmacokinetic profile

    Nemorexant Entry into man studies Phase 2 studies Phase 3 studies Ideal pharmacokinetic profile Plasma 1000 25 mg concentrations (ng/ml) 800 • Fast absorption 600 • Short half life • No accumulation over time 400 200 0 0 24 48 72 96 120 144 168 Time (h) Nemorexant is investigational, in development

  14. Slide 14: Fast and time limited pharmacodynamic effect

    Nemorexant Entry into man studies Phase 2 studies Phase 3 studies Fast and time limited pharmacodynamic effect Speed of eye 25 mg movements (degree/sec) Adult Healthy Volunteer – Daytime dosing Elderly Healthy Volunteer – Daytime dosing Time (h) Person performing eye movement test Nemorexant is inve

  15. Slide 15: No pharmacodynamic effect on next morning

    Nemorexant Entry into man studies Phase 2 studies Phase 3 studies No pharmacodynamic effect on next morning Karolinska Sleepiness Scale Placebo 25 mg Score 9 Very sleepy 8 7 Sleepy, but no effort keeping awake 6 Neither alert nor 5 sleepy 4 Alert, 3 normal level 2 1 Very alert Time after first dose

  16. Slide 16: Purpose and objectives of the Phase 2 program

    Purpose and objectives of the Entry into man studies Phase 2 studies Phase 3 studies Phase 2 program Purpose Objectives To provide necessary information To characterize the dose response to adequately design the confirmatory on objective and subjective sleep trials parameters To document the safety

  17. Slide 17: Two phase 2 studies completed

    Two phase 2 studies completed Entry into man studies Phase 2 studies Phase 3 studies Informative design Adult study: classical parallel group design Elderly study: cross over design • 4-week treatment to assess durability of effect • 2-night treatment • Short treatment withdrawal at the end • 4 dose

  18. Slide 18: Efficacy results in adult patients

    Efficacy results in adult patients Entry into man studies Phase 2 studies Phase 3 studies • Statistically significant dose- response on primary endpoint (objective WASO by PSG) • Clinically relevant effect especially at 25 and 50 mg • Other sleep endpoints and assessments at subsequent time points g

  19. Slide 19: Efficacy results in elderly patients

    Efficacy results in elderly patients Entry into man studies Phase 2 studies Phase 3 studies • Statistically significant dose- response on primary endpoint (objective WASO by PSG) • Clinically relevant effect especially at 10, 25 and 50 mg • Other objective sleep parameters generally aligned to prima

  20. Slide 20: Normal sleep architecture preserved

    Normal sleep architecture preserved Entry into man studies Phase 2 studies Phase 3 studies S1 S2 SWS REM Total Sleep Time (min) placebo 10.7 57.4 12.6 19.3 357 5 mg nemorexant 10 55.1 15 19.9 371 10 mg nemorexant 10.7 56.8 12.5 20 384 25 mg nemorexant 9.8 55.4 12.5 22.3 387 50 mg nemorexant 10 56.2

  21. Slide 21: Overview of adverse events in adults

    Overview of adverse events in adults Placebo Nemorexant Nemorexant Nemorexant Nemorexant Zolpidem 5 mg 10 mg 25 mg 50 mg 10 mg N = 60 N = 60 N = 58 N = 60 N = 61 N = 60 Subjects with at least one AE [n (%)] Treatment-emergent AE 18 (30.0) 21 (35.0) 22 (37.9) 23 (38.3) 21 (34.4) 24 (40.0) Treatment e

  22. Slide 22: Overview of adverse events in elderly

    Overview of adverse events in elderly Placebo Nemorexant Nemorexant Nemorexant Nemorexant 5 mg 10 mg 25 mg 50 mg N = 54 N = 56 N = 54 N = 55 N = 56 Subjects with at least one AE [n (%)] Treatment emergent AE 8 (14.8) 13 (23.2) 12 (22.2) 10 (18.2) 16 (28.6) Treatment emergent AE of special interest a

  23. Slide 23: Phase 2 conclusion

    Nemorexant Entry into man studies Phase 2 studies Phase 3 studies Phase 2 conclusion Efficacy • Dose response confirmed in adults and elderly subjects on objective sleep primary endpoint : WASO • Other endpoints results generally aligned to primary endpoints Safety (in the limit of the study design)

  24. Slide 24: Phase 3 program concept: adults and elderly patients

    Nemorexant Entry into man studies Phase 2 studies Phase 3 studies Phase 3 program concept: adults and elderly patients – 3 dose levels selected Efficacy 1. Objective sleep parameters 2. Subjective sleep parameters 3. Daytime functioning assessed by a patient reported outcome instrument specifically

  25. Slide 25: Phase 3 program overview

    Nemorexant Entry into man studies Phase 2 studies Phase 3 studies Phase 3 program overview Main studies (12 weeks) Extension study (40 weeks) 301: placebo, 25 mg & 50 mg 303: placebo, 10 mg, 25 mg & 50 mg 302: placebo, 10 mg & 25 mg Design Duration • 3 double-blind, randomized, placebo-controlled, •

  26. Slide 26: Main studies 301 & 302 study design

    Main studies 301 & 302 Entry into man studies Phase 2 studies Phase 3 studies Study design Screening 20-31days Treatment Period 84 days Safety Follow-up 30 days Run-in Placebo or Low (LD) or high dose (HD) nemorexant Run-out Double-blind Randomization 1st month 2nd month 3rd month EOT EOS V1 V2 V3 V

  27. Slide 27: Extension study 303 study design

    Extension study 303 Entry into man studies Phase 2 studies Phase 3 studies Study Design ID-078A301/02 Treatment Period 40 weeks Safety Follow up 30 days Run out period Either Placebo, 10, 25 or 50mg nemorexant Run out No treatment Double-blind No blinding Randomization Week 2 Week 13 Week 26 Week 40

  28. Slide 28: Nemorexant: in summary

    Nemorexant In summary: • From preclinical to phase 2: translation of product properties − Promotes sleep and maintains a natural sleep architecture − PK/PD profile optimized to combine effect during the night with low residual next morning plasma concentration/no “hang-over” effect Insomnia Compound

  29. Slide 29: Patient quote on insomnia

    “It really annoys me when people say ‘if you were really tired, you would sleep’. If only it were that simple! Unless you have suffered from true insomnia, you have absolutely no idea what it’s like.” - Patient 29 Phase 3 initiation in insomnia | June 2018

Idorsia — Technical Presentation (June 2018) on 6ix